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Among the many unprecedented aspects of the 
SARS- CoV-2 pandemic is the intense virological mon-
itoring that has occurred, with more than two million 
virus isolates having undergone partial or complete 
genomic sequencing. Initially, genetic sequencing sug-
gested that SARS- CoV-2 was exceptionally well adapted 
to humans, spreading rapidly with little evidence for nat-
ural selection among circulating viruses. This changed 
during the later months of 2020, with the first reports 
of emergent SARS- CoV-2 variants associated with 
increased transmissibility, disease severity and escape 
from humoral immunity.
In this Review, we create a framework for under-
standing SARS- COV-2 variants by describing funda-
mental aspects of SARS- CoV-2 evolution, the structure 
and function of the SARS- CoV-2 spike protein and the 
laboratory methods used to characterize spike variants. 
We then describe the biological properties and epidemi-
ological characteristics of these variants and their asso-
ciated mutations. Lastly, we describe the types of study 
required for the research, clinical and public health com-
munities to respond to the new threat posed by emerging 
SARS- CoV-2 variants. Given the wide public interest in 
this topic, we provide a box of key points. We also provide a 
repository of the SARS- CoV-2 variant neutralization data 
discussed in this Review (Stanford University Coronavirus 
Antiviral & Resistance Database — Susceptibility Data).
SARS- CoV-2 evolution
Coronaviruses contain an exonuclease enzyme that 
reduces their replication error rate by about 15- fold to 
20- fold in vitro, resulting in an in vivo viral mutation rate 
about 10- fold lower than that of influenza1–3. Nonetheless, 
they accumulate mutations and generate further diver-
sity through the process of recombination when vari-
ants with different mutations infect the same host4–6. 
Recombination between different SARS- related coro-
naviruses is likely to have led to the emergence of 
SARS- CoV-2 (ref.7) and, although it can be difficult to 
detect owing to the similarity of most sequences, recom-
bination is occurring to some extent among circulating 
SARS- CoV-2 variants6,8. Additionally, host- mediated 
RNA editing by APOBeC and ADAr enzymes, as evi-
denced by the dominance of C to U changes in specific 
dinucleotide contexts, contributes to SARS- CoV-2 
diversity9,10.
Although it had been previously assumed that wan-
ing immunity explained the observation that people 
are commonly reinfected with endemic common- cold 
coronaviruses11, recent studies suggest that antigenic 
drift also contributes to the lack of long- lasting protec-
tion following coronavirus infections12,13. HCoV-229E 
and HCoV- OC43 sequences over a 30- year period 
demonstrate a ladder- like phylogenetic tree topology 
consistent with the emergence of novel variants sweeping 
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Immunity mediated via host 
antibodies including those that 
directly neutralize virus as well 
as those that recruit other host 
immune functions.
Viral mutation rate
The rate of mutation calculated 
in vitro as the number of 
nucleotide incorporation errors 
per round of replication or 
in vivo as the number of 
nucleotide changes observed 
during a fixed time such as 
1 year. Although the two rates 
are related, the in vivo rate is 
also influenced by the number 
of replication cycles that occur 
over time and the frequency 
with which multiple mutations 
occur at the same position.
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through the human population similar to seasonal influ-
enza, albeit at a slower rate, with virus isolates from one 
time point often evading neutralization by plasma from 
persons infected several years earlier12,13.
The evolutionary rate of SARS- CoV-2 has been esti-
mated to be between 0.0004 and 0.002 mutations per 
nucleotide per year14–19. Although the possibility that 
synonymous mutations may influence SARS- CoV-2 
phenotypic properties should not be discounted, there 
have been no reports of this phenomenon occurring 
within the SARS- CoV-2 spike gene. Therefore, in this 
Review, we use the term mutation to indicate an amino 
acid change from the Wuhan- Hu-1 reference sequence 
(GenBank accession: NC_045512.2).
The phylogenetic classification of emergent SARS- 
CoV-2 lineages has been difficult because new line-
ages often differ from one another by just a few 
nucleotides20,21. Geographical classification has been 
challenging because most variants have been detected in 
multiple countries and there are marked disparities 
in the proportion of viruses undergoing sequencing in 
different countries. Two commonly used systems have 
been developed for epidemiological surveillance: the 
Phylogenetic Assignment of Named Global Outbreak 
(PANGO) lineage22 and NextStrain23 systems. The 
PANGO lineage system provides greater specificity and 
is used more frequently. It contains an alphabetical prefix 
and a suffix containing up to three numbers separated 
by periods indicating sub- lineages (such as B.1.1.7). 
However, as the system allows for only three hierarchical 
levels, the introduction of a new lineage suffix can make 
it difficult to identify the ancestral lineage of a variant. 
In addition, the lineage of a virus does not always corre-
spond to its component mutations, as a virus can acquire 
additional biologically relevant mutations without being 
assigned to a new lineage.
The first indication of SARS- CoV-2 genetic evolu-
tionary selection pressure became evident as a novel 
virus variant containing the spike mutation D614G 
emerged in early 2020 and rose to a prevalence of nearly 
100% by June 2020 (refs8,24–26). By the end of 2020 and 
in early 2021, several variants with recurrent muta-
tions (in addition to D614G) occurring primarily, but 
not exclusively, in the spike protein were also reported. 
In December 2020, B.1.1.7, a rapidly growing lineage in 
the UK associated with an unexpectedly large number 
of genetic changes, was reported on the virological.org 
discussion forum27. Retrospective analyses determined 
that the earliest clinical sample of this variant had been 
obtained in the UK in late September 2020.
Within 1 month, two additional rapidly growing 
lineages with large numbers of genetic changes were 
reported from South Africa16 and Brazil19. The B.1.351 
variant rose in prevalence in South Africa from 11% in 
October to 87% by December28. The P.1 variant emerged 
in Manaus, Brazil, a region that was estimated to have 
achieved an infection rate approaching 75% by October 
2020, but which experienced a surge in new cases begin-
ning in November 2020 (refs19,29,30). Subsequently, a novel 
variant (B.1.617.2) increased in prevalence from 2% in 
February 2021 to 87% in May 2021 in Maharashtra, 
India, as India experienced a dramatic surge in cases31. 
Since then, the B.1.617.2 variant has spread widely in 
multiple countries32–34 and displayed evidence of being 
even more transmissible than the B.1.1.7 variant, and 
is likely to cause more severe disease than earlier virus 
variants35,36.
Variants that have spread widely and displayed evi-
dence for being more transmissible, causing more severe 
disease and/or reducing neutralization by antibodies 
generated during previous infection or vaccination have 
been classified as variants of concern (VOCs) by the 
World Health Organization (WHO)37, US Centers for 
Disease Control and Prevention (CDC)38 and COVID-19 
Genomics UK Consortium (COG- UK)39. Variants that 
have spread less widely but contain mutations similar 
to those present within VOCs have been classified as 
variants of interest (VOIs). On 31 May 2021, the WHO 
labelled VOCs and VOIs using the Greek alphabet, with 
the current VOCs designated as Alpha (B.1.1.7), Beta 
(B.1.351), Gamma (P.1) and Delta (B.1.617.2) (fIg. 1).
Spike structure and immune epitopes
The SARS- CoV-2 spike protein is a 1,273- amino acid tri-
meric glycoprotein responsible for virus entry into host 
cells (fIg. 1). Each spike monomer has a largely exposed 
S1 attachment domain (residues 1–686) and a partially 
buried S2 fusion domain (residues 687–1,273)40,41. Part 
of S1, called the receptor- binding domain (RBD; residues 
306–534), alternates between a closed/down position and 
an open/up position. When in the up position, it binds 
to the human angiotensin- converting enzyme 2 (ACE2) 
receptor, the necessary first step for entry into most, if 




























APOBEC and ADAR 
enzymes
Apolipoprotein B mrNA- 
editing enzyme catalytic 
polypeptide- like (APOBeC)  
and adenosine deaminase 
acting on rNA (ADAr) are  
host enzymes that edit viral 
genomes. Although these 
enzymes represent an antiviral 
defence mechanism, it is often 
hypothesized that these 
enzymes can contribute to  
viral evolution.
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Fig. 1 | sARs-coV-2 variants: evolution and constituent mutations. 
a | Phylogenetic tree based on subsampling of globally circulating 
sequences created by NextStrain (CC BY 4.0). The tree shows that 
nearly all variants of concern (VOCs; Alpha, Beta, Gamma and Delta) 
and variants of interest (VOIs; Kappa, Epsilon, Eta, Theta, Iota and 
Lambda) emerged independently beginning in late 2020. b | The most 
common mutations present in multiple VOCs and VOIs. Numeric 
column headers indicate spike protein positions except for two 
non- spike mutations in the nsp6 and nucleocapsid (N) genes. The 
second row indicates the residue found in the reference sequence. 
Spike protein residues are mapped to their associated domain within 
the spike protein, as shown in various shades of grey above the table. 
Deletions are indicated 'del'. Several additional mutations in other viral 
proteins also appear to have arisen more than once, including 
orf3a:Q57H and nsp2:T85I. NTD, amino- terminal domain; PANGO, 
Phylogenetic Assignment of Named Global Outbreak;  RBD, 
receptor- binding domain; RBM, receptor- binding motif;  SD, 
subdomain; S1/S2, junction between the exposed S1 attachment 
domain and the partially buried S2 fusion domain; WHO, World Health 
Organization.
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contacts with the human ACE2 receptor. The part of the 
RBD containing these residues encompasses residues 
438–506 and is called the receptor- binding motif (RBM), 
whereas the remainder of the RBD is called the RBD core.
Similar to the RBD, much of the S1 amino- terminal 
domain (NTD) is also exposed on the S trimer surface. 
The remainder of S1 contains two subdomains down-
stream of the RBD traditionally referred to as subdomain 1 
(SD1) and subdomain 2 (SD2) that we refer to in this 
Review as the S1 carboxy- terminal domain (CTD). The 
spike protein also has 22 glycosylation sites, distributed 
among both the S1 and S2 domains. Within S1, eight of 
the glycans are found in the NTD, two are in the RBD 
core, three are in the CTD and nine are in S2 (ref.46).
S1 displays more amino acid variability than S2 
among SARS- related coronaviruses (fIg. 2). Within S1, 
the RBD and the NTD are more variable than the CTD. 
Within the RBD, the RBM is more variable than the RBD 
core. As of June 2021, 42 spike mutations have a global 
sampled prevalence ≥1.0% including 15 in the NTD, 
6 in the RBD, 5 in the CTD and 9 in S2 (Supplementary 
Table 1). Most of the 32 S1 mutations with a prevalence 
≥1.0% arose in multiple SARS- CoV-2 lineages.
The spike RBD is the main target of neutralizing 
antibodies47–52. The presence of neutralizing monoclonal 
antibodies (mAbs) targeting the RBD correlates with 
protection in animal models and in previously infected 
and vaccinated persons, although cellular immune 
responses and potentially non- neutralizing antibod-
ies are likely to have contributed to protection in these 
studies53–59. The development of neutralizing antibodies 
early in the course of infection has been associated with 
lower virus levels and greater protection from severe 
infection58,60–63. Finally, the passive administration of 
neutralizing mAbs reduces the severity of infection 
when administered early62,64–66.
High- resolution X- ray crystallography and 
cryo- electron microscopy structures have been pub-
lished for more than 100 mAbs, including 5 with US 
Food and Drug Administration (FDA) Emergency Use 
Authorizations (EUAs) and several additional mAbs 
in phase III clinical trials67. Most mAbs target either 
the RBD RBM or the RBD core; several target  the 
NTD. Those targeting the RBM compete with RBD 
binding to ACE2. Those targeting the RBD core often 
cross- neutralize other SARS- related coronaviruses49,68,69. 
The NTD- targeting neutralizing antibodies primarily 
bind a single epitope comprising the largest glycan- free 
surface facing away from the viral membrane referred to 
as the NTD supersite51,52,70.
Several classification schemes have been developed to 
describe RBD- binding mAbs based upon whether they 
bind the RBM or RBD core, whether they bind the RBD in 
its up and/or down configuration and the extent to which 
they compete with other mAbs71–74. Among those mAbs 
targeting the RBM, one group binds epitopes that overlap 
extensively with the ACE2 binding site and, as a result, 
binds solely when the RBD is in the open state. This group, 
which is referred to as class 1 mAbs, is typically encoded 
by the closely related IGHV3-53 and IGHV3-66 heavy 
chain genes and has short complementarity- determining 
region H3 loops. The second main group of RBM- binding 
mAbs (class 2) has a smaller ACE2 binding footprint and, 
as a result, can often bind the RBD in the closed state. 
Several other RBM- binding mAbs are more difficult to 
classify, including a class that binds a quaternary epitope 
involving more than one RBD71,72.
Antibodies that target the RBD core also form 
two major clusters, one on the surface- accessible 
face of the RBD and another whose epitope is bur-
ied in the closed state71–74. Antibodies that bind to the 
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Fig. 2 | Genetic variability of the sARs spike proteins. Position- specific 
sequence variability and median domain- specific pairwise distances 
among SARS- related coronaviruses. Results were derived from an 
alignment of 24 representative sarbecovirus spike sequences having a 
nucleotide genetic distance (TN93 model) of ≥0.01. Position- specific 
entropy is superimposed for one of three monomers on a surface 
representation of trimeric SARS- CoV-2 spike (Protein Databank (PDB) 
code: 6XR8), with white indicating conserved residues and the shade of red 
indicating the extent of sequence variability. Two 90o rotated side views 
(left and middle panels) and one top view (right panel) of the spike trimer 
are shown. The median pairwise distance among SARS- related 
coronaviruses is greatest for the S1 amino- terminal domain (NTD) and 
receptor- binding domain (RBD). Within the RBD, the median pairwise 
distance is greater for the receptor- binding motif (RBM) than for the core 
region. CTD, carboxy- terminal domain; S1, exposed attachment domain; 
S2, partially buried fusion domain.
Neutralizing antibodies
Antibodies that alone can 
prevent virus infection of cells 
in vitro. Neutralization is 
determined almost entirely  
by an antibody fragment 
antigen- binding (fab) region.
Epitope
An antigenic determinant  
of a protein. B lymphocyte 
antibody epitopes are often 
formed by amino acids from 
different parts of a protein that 
are brought together during 
protein folding. T lymphocyte 
epitopes are linear peptides 
recognized by T lymphocyte 
receptors when bound to  
a human leukocyte antigen  
(HLA) protein on a cell surface. 
As human HLA proteins are 
heterogenous, different people 
recognize different epitopes of 
the same protein.
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the open or closed state and those that target the RBD 
core epitope bind only in the open state. fIgure 3 dis-
plays the epitopes of those mAbs with high- resolution 
structures that are either in advanced clinical trials or 
have been assessed for their activity against viruses 
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b  RBM class 2
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Fig. 3 | sARs-coV-2 spike-targeted antibody classifications. Classification of monoclonal antibodies (mAbs) targeting 
the SARS- CoV-2 spike receptor- binding domain (RBD) epitopes. For the two classes of mAbs binding the receptor- binding 
motif (RBM), 90o rotated side views and one top view of a surface RBD representation are shown (parts a,b). For the  
two classes of RBD core- binding mAbs, just the 90o rotated side views are shown (parts c,d). Each image derived from 
coordinates of the Protein Databank (PDB) structure 6M0J. Bold highlighted mAbs are in phase III clinical trials (as of  
July 2021). Blue intensity is proportional to the number of mAbs binding to the underlying amino acid residues. RBM refers 
to the region of the RBD containing the angiotensin- converting enzyme 2 (ACE2)- binding residues. RBM class 1 mAbs 
(part a) bind the RBD only in its up position, whereas RBM class 2 mAbs (part b) can bind the RBD in its up or down position. 
A third RBM mAb class binds to a quaternary epitope comprising more than one RBD but is not shown as it would require 
the trimeric spike. Epitopes for amino- terminal domain- binding mAbs are not shown.
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describes the epitopes of those mAbs being studied in 
clinical trials.
In addition to RBD- targeting and NTD- targeting 
antibodies, there may be a protective role for neutral-
izing antibodies targeting other parts of the spike and 
for non- neutralizing antibodies. Several neutralizing 
antibodies bind the S1 CTD and S2 of multiple coro-
naviruses, although these have been much less potent 
than RBD- targeting and NTD- targeting mAbs75–77. 
Non- neutralizing antibody fc- effector functions such 
as complement activation, cellular cytotoxicity and 
phagocytosis have also been shown to afford pro-
tection in animal models78,79 and in the initial weeks 
following vaccine administration80. However, the pro-
tection afforded by non- neutralizing antibodies in 
the absence of neutralizing antibodies is difficult to 
quantify81,82.
The early development of cytotoxic T lympho-
cyte (CTL) responsiveness in persons infected with 
SARS- CoV-2 correlates with less severe COVID-19 
illness83,84. CTL responses also contribute to protec-
tion from severe infection in non- human primates in 
the presence of low titres of neutralizing antibodies53,85 
and in persons with impaired humoral immunity86. 
SARS- CoV-2 infection and immunization with the 
spike protein elicits helper T lymphocyte and CTL 
responses58,87,88. Indeed, many studies have identified 
specific human leukocyte antigen (HLA)- restricted 
helper T cell and CTL spike epitopes58,89,90. Analyses of 
peptide libraries from several VOCs have shown that, 
with a few exceptions, spike CTL epitopes either remain 
unchanged or able to bind most HLA molecules91,92. 
Nonetheless, the number of T cell spike epitopes recog-
nized by a person varies according to their HLA profile 
and is much lower than the total number of SARS- CoV-2 
T cell epitopes93,94. Mutations at T cell epitopes have also 
been observed within several cohorts with the com-
mon HLA type A*02 (ref.95) and at low levels within the 
circulating viruses of individual patients96.
In vitro selection and neutralization experiments
An increasing number of studies have described either 
the in vitro selection of SARS- CoV-2 immune escape 
spike mutations or the impact of mutations on the neu-
tralizing activity of mAbs, convalescent plasma or plasma 
from vaccinated persons52,97,98. Studies of plasma from 
patients who were previously infected provide insight 
into the risk of reinfection with a SARS- CoV-2 variant, 
whereas those from immunized persons are relevant to 
vaccine efficacy. Although most convalescent plasma 
samples studied so far were obtained prior to the emer-
gence of immune escape variants (‘pre- variant isolates’), 
more recent studies have studied plasma from patients 
infected with different VOCs99–104.
In vitro selection experiments have been perfor-
med most commonly using non- replicative pseudo- 
typed or replication- competent chimeric viruses105–108. 
SARS- CoV-2 pseudo- typed viruses are produced by 
co-transfecting a SARS- CoV-2 protein expression vec-
tor and a construct encoding the components required 
for replication of a different virus that lacks the cod-
ing sequence for their own surface protein — most 
commonly vesicular stomatitis virus (VSV), HIV-1 or 
murine leukaemia virus. These constructs also encode a 
reporter gene such as luciferase or green fluorescent pro-
tein. Chimeric viruses contain the SARS- CoV-2 spike 
sequence in a VSV genome lacking the sequence for the 
VSV surface protein107,108. VSV- based chimeric viruses 
are particularly useful for mutation selection studies 
because they can undergo multiple rounds of replica-
tion. There have also been reports describing the in vivo 
selection of spike mutations in animal models109 and in 
persons infected with SARS- CoV-2 with prolonged 
infections or receiving mAbs109–114.
Neutralization studies compare the ability of a mAb 
or plasma sample to inhibit the cellular entry of a virus 
containing one or more spike mutations with viruses 
lacking these mutations. Neutralization studies have 
been performed using either pseudo- typed viruses, 
VSV- based chimeric viruses, full- length cloned recom-
binant SARS- CoV-2 viruses115–120 or low- passage or 
plaque- purified cultured isolates121–124. Pseudo- typed 
and chimeric viruses have been used most frequently 
because it is simpler to introduce mutations into a plas-
mid encoding just the spike gene compared with using 
a clinical virus isolate or a recombinant virus gener-
ated using a system that requires either multiple plas-
mids or bacterial or yeast artificial chromosomes119,120. 
Although the results of neutralization experiments 
using pseudo- typed viruses, VSV- based chimeric 
viruses and full- length SARS- CoV-2 usually yield sim-
ilar results97,107,125,126, full- length viruses are expected to 
be more reliable and can be studied in animal models127.
The effects of nearly all individual RBD mutations on 
protein expression in yeast (a correlate of protein folding 
stability), ACE2 binding and binding to a wide variety of 
mAbs and plasma samples have also been assessed using 
deep mutational scanning in which each yeast cell pro-
ducing a different RBD mutation is labelled with a dis-
tinct genomic sequence50,128–131. Although this approach 
does not quantify the effect of RBD mutations on mAb 
neutralization, it has proved useful as a screening assay 
to identify mutations that require further study in cell 
culture. High- throughput biochemical assays such as 
enzyme- linked immunosorbent assays (ELISAs) are also 
being developed to allow clinical laboratories to measure 
the ability of plasma to inhibit ACE2 binding to RBDs 
belonging to different SARS- CoV-2 variants132–134.
In vitro neutralization experiments of SARS- CoV-2 
variants are usually reported as a fold reduction in 
susceptibility compared with a control virus, such as 
the reference Wuhan- Hu-1 virus, variants containing 
just the D614G mutation or other pre- variant isolates97. 
In the sections that follow, we summarize the neutrali-
zation susceptibility of different viruses as being <3- fold, 
3–10- fold and >10- fold reductions compared with the 
control virus as these thresholds represent approxi-
mately one- half- log and one- log reductions in suscep-
tibility. Nonetheless, the absolute level of neutralization 
is often more clinically relevant than the fold change 
compared with a control virus as the same reduction in 
susceptibility to a mAb or to vaccinee plasma will be 
more consequential for mAbs with low intrinsic activity 
or vaccines that do not elicit high levels of neutralizing 
Fc- effector functions
Antibody functions mediated 
by their fragment crystallizable 
(fc) region, including 
complement activation, 
antibody- dependent  
cellular cytotoxicity and 
antibody- dependent cellular 
phagocytosis. These functions 
may be particularly important 
for eliminating virally infected 
cells. They are more difficult  
to study in vitro than in vivo.
Convalescent plasma
Plasma samples from persons 
previously infected with 
sArs- CoV-2 usually contain 
neutralizing antibodies that 
bind to the sArs- CoV-2 spike 
protein and prevent it from 
infecting cells in vitro. 
Convalescent plasma samples 
are characterized by the 
number of months since 
recovery from infection, the 
severity of illness associated 
with infection, and the extent 
to which the plasma can be 
diluted and still retain the 
ability to prevent infection 
in vitro against different 
sArs- CoV-2 variants.
Deep mutational scanning
A method that makes use of 
next- generation sequencing to 
measure in a single experiment 
the activity of many unique 
variants of a protein.
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antibodies. In summarizing the results of neutralizing 
experiments, we have also pooled results obtained using 
pseudo- typed, chimeric and infectious viruses as the 
results of these assays are usually concordant97,107,125,126.
Of the more than 6,000 plasma samples from per-
sons receiving a complete course of vaccination, 76% 
were obtained from persons receiving an authorized 
mRNA vaccine (Pfizer/BioNTech BNT162b (54%) and 
Moderna mRNA-1273 (22%)), 9% from recipients of the 
adenovirus- vectored AstraZeneca AZD1222 vaccine, 
6% from recipients of the inactivated Sinovac CoronaVac 
vaccine, 3% from recipients of the adenovirus- vectored 
Janssen Ad26.CoV2.s vaccine, 3% from recipients of 
the inactivated Bharat Biotech Covaxin (BBV152) 
vaccine and 1% each from recipients of the protein 
subunit Novavax NVX- CoV2373, the adenovirus- 
vectored Gamaleya Research Institute Sputnik V and the 
inactivated Sinopharm BBIBP- CorV vaccines.
SARS- CoV-2 mutations
Currently circulating SARS- CoV-2 VOCs and VOIs 
share several mutations that enable them to spread in the 
face of rising population immunity while maintaining 
or increasing their replication fitness. These mutations 
belong to a repertoire of recurrent mutations, most of 
which are in the spike gene. fIgure 4 illustrates the most 
biologically and clinically significant spike mutations 
and their change in prevalence since the early stages of 
the pandemic. To understand the biological properties 
and epidemiological characteristics of the increasing 
number of SARS- CoV-2 VOCs and VOIs, it is neces-
sary to understand their component mutations. Here, 
we divide these mutations into seven categories: D614G; 
the RBD mutation N501Y; the RBD mutation E484K; 
other RBD mutations; NTD mutations; mutations 
proximal to the S1/S2 furin cleavage site; and non- spike 
mutations.
D614G
The prevalence of the D614G mutation began increas-
ing in late February 2020, and within several months it 
outcompeted all ancestral viruses and rose to a global 
prevalence approximating 100%8. Infectious virus clones 
with D614G replicated to higher levels in primary 
human airway cells and in the upper respiratory tracts 
of hamsters135–137. D614G- containing virus clones were 
also associated with increased transmission between 
hamsters136. Cryo- electron microscopy studies have 
shown that D614G disrupts one or more interprotomer 
contacts, resulting in a greater likelihood that one or 
more of the three RBDs are in an open versus closed 
position and, hence, compatible with ACE2 receptor 
binding138,139. Subsequently, additional mutations in 
the spike CTD and in S2 have also been reported to 
possibly increase SARS- CoV-2 replication by a simi-
lar mechanism140. D614G may also be responsible for 
increasing the number of spike proteins per virion141,142 
and the rate of S1/S2 cleavage143. Viruses with D614G 
have been slightly more susceptible to neutralization 
by mAbs, convalescent plasma and plasma from vacci-
nated individuals in some studies138,144 and slightly more 
resistant to neutralization in other studies136,145.
N501Y
N501Y is present in the Alpha, Beta and Gamma VOCs. 
N501Y increases ACE2 affinity128,146,147 and increases 
virus replication in human upper- airway cells and in 
the upper respiratory tracts of hamsters127. N501Y does 
not influence the binding and neutralization of most 
mAbs48,109,117,121,148,149 (TABLe 1). Alone, it is also rarely 
associated with reduced susceptibility to convalescent 
plasma121,148–150 or plasma from persons receiving one of 
the two authorized mRNA vaccines (Pfizer/BioNTech 
BNT162b2 or Moderna mRNA-1273) or the Novavax 
NVX- CoV2373 protein subunit vaccine115,121,148,150–153 
(fIg. 5).
E484K
E484 is recognized by a high proportion of the poly-
clonal antibodies developing within persons infected 
with SARS- CoV-2 (ref.50). E484K is present in the Beta 
and Gamma VOCs16,19 and in the VOIs Eta (B.1.525), 
Iota (B.1.526)154, Theta (P.3)155,156 and Zeta (p.2)157. 
E484K has also been reported within several Alpha var-
iant sub- lineages158,159. E484Q has been reported in the 
Kappa VOI (B.1.617.1).
E484K has been selected in vitro by casirivimab and 
bamlanivimab and several other RBM class 1 and 2 
mAbs48,105,110,130,160 and it reduces susceptibility to these 
mAbs64,105,109,117,121 (TABLe 1). E484K has resulted in 3- fold 
to 10- fold reduced susceptibility to about 30% and 
>10- fold reduced susceptibility to about 10% of con-
valescent plasma samples121,130,160–162 (fIg. 5). E484K has 
also resulted in 3- fold to 10- fold reduced susceptibility 
to about 30% of plasma samples from persons immu-
nized with one of the authorized mRNA vaccines121,160–162 
(fIg. 5).
Other RBD mutations
L452R is present in the Delta VOC, as well as the Kappa 
(B.1.617.1) and Epsilon (B.1.427/9) VOIs34,123. It reduces 
susceptibility to several RBM class 2 mAbs, including 
bamlanivimab, but not to the other FDA EUA- approved 
mAbs109,110,160,163 (TABLe 1). L452R has resulted in 3- fold 
to 10- fold reduced susceptibility to about one third of 
convalescent and vaccinee plasma samples164–166 (fIg. 5). 
Pseudo- typed viruses containing L452R were associ-
ated with higher levels of cell entry in lung organoids 
compared with pseudo- typed viruses containing D614G 
alone but lower levels compared with pseudo- typed 
viruses containing N501Y (ref.123).
K417N/T are present in the Beta (as K417N) and 
Gamma (as K417T) VOCs. K417N/T rarely occur in the 
absence of other RBM mutations, possibly because K417 
mutations appear to reduce ACE2 binding130,159. K417N 
confers >100- fold reduced susceptibility to etesevimab129 
and about 10- fold reduced susceptibility to casirivimab121 
but retains susceptibility to bamlanivimab, imdevimab 
and sotrovimab121. K417N/T retain full susceptibility to 
plasma samples from persons previously infected with 
SARS- CoV-2 or immunized with one of the authorized 
mRNA vaccines117,121,167.
N439K increases ACE2 affinity128,168,169 and reduces 
imdevimab susceptibility129 (TABLe 1). Viruses containing 
N439K usually retain full susceptibility to convalescent 
Furin cleavage site
A short positively charged 
amino acid sequence at a 
specific location in a viral 
surface protein that is 
recognized by host furin 
protease enzymes. A furin 
cleavage site at the border of 
the sArs- CoV-2 spike s1 and 
s2 domains must be cleaved  
to enable viral cell fusion.
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plasma50,148,169. Increases in the prevalence of two lin-
eages containing N439K were reported in the UK in 
September 2020, but their prevalence declined with the 
emergence of the Alpha variant (ref.169).
Y453F emerged independently several times in mink 
lineages, including one that subsequently spread among 
humans but is no longer active170. Y453F increases ACE2 
binding but, nonetheless, remains rare128,140,171. Y453F 
markedly reduces susceptibility to casirivimab but not 
to the other FDA EUA- approved mAbs105,167 (TABLe 1).
S477N was present in a variant that spread widely in 
Europe in the summer of 2020 (ref.172). It increases the 
strength of ACE2 binding128 but has since circulated at a 
low level. It has not been shown to reduce susceptibility 
to any of the FDA EUA- approved mAbs109,167.
T478K is present in the Delta variant and a common 
variant in Mexico34,173. By itself, it retains susceptibility 
to all but a few mAbs and to most convalescent and 
vaccinee plasma samples50,129,130,174.
F490S and S494P are uncommon RBM mutations that 
have arisen independently within several Alpha variant 
sub- lineages158. F490S is associated with highly reduced 
susceptibility to bamlanivimab but retains susceptibil-
ity to the other FDA EUA- approved mAbs64,105,175. S494P 
is associated with >10- fold reduced susceptibility to 
bamlanivimab and about 5- fold reduced susceptibility 
to casirivimab64,109,175.
NTD mutations
NTD deletions are present in several VOCs and VOIs, 
and have also been reported commonly in persons with 
prolonged SARS- CoV-2 infections112–114,176. Deletions at 
positions 69–70 appear to be associated primarily with 
increased virus replication113,177 whereas those between 
positions 141–146 and 242–244 interfere with the neutral-
izing activity of NTD- binding antibodies51,121,178,179. Other 
NTD mutations including L18F and D253Y also reduce 
susceptibility to NTD- neutralizing antibodies51,103,158.
Mutations close to the S1/S2 furin cleavage site
Mutations just upstream of the polybasic S1/S2 furin 
cleavage — including Q675H/R, Q677H/P, N679K 
and P681H/R — have occurred independently in 
many SARS- CoV-2 variants180. P681H is present in the 
Alpha VOC and the Theta VOI, and in several addi-
tional SARS- CoV-2 lineages156. P681R is found in the 
Delta VOC and the Kappa VOI. The increased positive 
charge associated with both P681H and P681R appears 
to influence virus tropism by increasing S1/S2 cleavage 
in human airway epithelial cells181–183.
Non- spike mutations
Mutations outside the spike protein have been reported 
to increase SARS- CoV-2 transmissibility by antagoniz-
ing the host response to type I interferons. In one study, 
the Alpha and Beta variants displayed a mean 112- fold 
and 8- fold reduced susceptibility to several type I inter-
ferons, respectively, compared with an early pandemic 
virus184. In a second study, the Alpha variant was found 
to cause lower levels of interferon- β (IFNβ) expression 
and to be less sensitive to IFNβ pretreatment compared 
with two early pandemic viruses185. In this and in a third 
study, a D3L mutation in the Alpha variant nucleocapsid 
gene was found to introduce an enhanced transcription 
regulatory sequence (TRS) upstream of Orf9b, an inter-
feron antagonist gene expressed as an alternative reading 
frame within the nucleocapsid coding region185–187.
Although the nucleocapsid D3L mutation is not 
found in other VOCs or VOIs, most have mutations 
in genes associated with interferon antagonism. One 
example is a recurrent deletion (Δ106–108) of unknown 
phenotypic consequence in nsp6, a component of the 
SARS- CoV-2 membrane- tethered complex that also 
antagonizes interferon188 and is present in the Alpha, 
Beta and Gamma VOCs and the Eta, Iota and Lambda 
VOIs25 (fIg. 1b). Another example is a recurrent adjacent 
three- nucleotide change in the nucleocapsid gene that 
probably arose by homologous recombination of the core 
sequence of the leader TRS and that results in  the 
double amino acid change R203K/G204R and novel 
sub- genomic transcripts of unknown consequences189,190.
SARS- CoV-2 variants
SARS- CoV-2 variants are classified according to their 
lineage and component mutations. As a result, viruses 
belonging to the same lineage but containing differ-
ent subsets of mutations can be classified as different 
variants. Variants are characterized by their transmis-
sibility, disease severity and ability to evade humoral 
immunity. Increased transmissibility is demonstrated 
by the ability of a variant to outcompete other variants 
and to display a higher effective reproduction rate and/or 
secondary attack rate compared with other circulating 
variants8,191–193. Disease severity has been assessed using 
mortality data and rates of hospitalization194,195. Variants 
associated with higher virus levels may be more trans-
missible and/or cause more severe disease. Evasion of 
humoral immunity has been assessed by comparing a 
variant’s susceptibility to mAbs, convalescent plasma and 
vaccinee plasma with that of other variants52,97. In the fol-
lowing sections, we summarize the biological, epidemio-
logical and clinical characteristics of the WHO- defined 
VOCs and VOIs as of June 2021.
Alpha variant (B.1.1.7)
The Alpha variant spike mutations include the RBD 
mutation N501Y, P681H and NTD deletions at positions 
69–70 and 144 (fIg. 1b). The position 69–70 deletion pre-
vents the amplification of one of three genomic segments 
Fig. 4 | Locations and prevalence of key sARs-coV-2 spike mutations. a | Sites of  
16 key S1 (exposed attachment domain) mutations on the SARS- CoV-2 spike trimer, 
including 9 in the receptor- binding domain (RBD; green), four in the amino- terminal 
domain (NTD; cyan) and three in the carboxy- terminal domain (CTD; purple). Spike  
trimer figure derived from a cryo- electron microscopy structure (Protein Databank (PDB) 
code 7BNN). S2 (partially buried fusion domain) shown in dark grey. Six of the RBD muta-
tions (K417N/T, L452R, T478K, E484K and N501Y) are present in one or more of the World 
Health Organization (WHO) variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351), 
Gamma (P.1), and Delta (B.1.617.2). NTD mutations include three deletions and L18F, 
mutations present in two or more VOCs. CTD mutations include D614G, which became 
the consensus amino acid at this position prior to the emergence of the VOCs, and 
P681H and P681R, which are present in Alpha and Delta VOCs, respectively. b | Other 
than D614G, which has a prevalence close to 100%, the most prevalent mutations as  
of June 2021 are those present in Alpha (Δ69/70, Δ144, N501Y and P681H) and Delta 
(L452R, T478K, and P681R) VOCs. Prevalence data obtained from outbreak.info196.
Transcription regulatory 
sequence
(Trs). In coronavirus genomes, 
a short sequence located at 
several genomic locations that 
is responsible for producing a 
set of nested 3′ and 5′ 
co- terminal sub- genomic rNA 
molecules.
Effective reproduction rate
The average number of new 
infections caused by an 
infectious individual in a 
population where some 
individuals may no longer be 
susceptible. The effective 
reproduction rate of different 
variants is compared to control 
for factors other than 
transmissibility that might 
account for changes in the 
prevalence of different variants.
Secondary attack rate
The transmission of infection in 
a circumscribed group. The 
secondary attack of different 
variants is compared to control 
for factors other than 
transmissibility that might 
account for changes in the 
prevalence of different variants.
◀
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in a commonly used diagnostic PCR assay, resulting in a 
phenomenon referred to as S- gene target failure (SGTF), 
which has been used as a proxy for this variant191. The 
Alpha variant also contains several non- spike mutations 
including nsp6:Δ106–108 and the nucleocapsid muta-
tions D3L, R203K and G204R, which may increase 
transmission by antagonizing innate immunity25,185–187. 
By the second quarter of 2021, the Alpha variant 
accounted for the majority of infections in the USA and 
many European countries23,196. Epidemiological studies 
suggest that it was approximately 50% more transmis-
sible than previously circulating UK variants191,197,198. 
It was also associated with threefold to eightfold higher 
upper- airway levels199–201 and an estimated 50% increased 
mortality194,195,202.
The Alpha variant is susceptible to neutralization by 
most neutralizing mAbs as well as by most plasma sam-
ples from previously infected persons97,102,121,149,159,203–206 
(fIg. 5). The fact that the Alpha variant is rarely associated 
with reduced susceptibility to convalescent plasma is 
consistent with it not being associated with an increased 
risk of reinfection207.
The Alpha variant has displayed 3-fold to 10-fold 
reduced susceptibility to approximately 15% of plasma 
samples from recipients of an authorized mRNA 
vaccine97,102,121,148,149,152,159,204,208,209. In cohort studies from 
Israel and Qatar, the BNT162b vaccine also retained 
greater than 90% efficacy against this variant210,211 
(TABLe 2). In a post- hoc analysis of a NVX- CoV2373 clin-
ical trial, vaccine efficacy was 86.3% against Alpha vari-
ants compared with 96.4% against non- Alpha variants212 
(TABLe 2). Similar data for the AZD1222 vaccine have 
been inconsistent. In a study of vaccine trial participants, 
plasma samples were associated with a median reduc-
tion in neutralizing activity of ninefold to the Alpha 
variant compared with an earlier UK variant213. In this 
trial, AZD1222 displayed a non- statistically significant 
reduction in efficacy against the Alpha variant (70%; 
95% confidence interval (CI) 44–85%) compared with 
earlier variants (82%; 95% CI 68–89%)213. However, in 
three other studies, the median reduction in neutralizing 
activity was between onefold and threefold102,214,215.
Several Alpha variant sub- lineages have acquired 
additional mutations that might increase the risk of rein-
fection and vaccine failure, including the RBD mutations 
E484K, F490S and S494P (ref.158).
Beta variant (B.1.351)
Between October 2020 and January 2021, daily cases 
in South Africa increased from approximately 2,000 
to more than 20,000 reported cases per day. This 
increase occurred in a setting in which more than 30% 
of the population was estimated to have already been 
infected and was associated with the emergence of 
the Beta variant, which contains three RBD mutations 
(K417N, E484K and N501Y) and five NTD mutations, 
Table 1 | sARs- coV-2 variants and their fold reduction in neutralization susceptibility to monoclonal antibodies in advanced  
clinical trials







112 3.69 1.33 114 0.815 18 2.712
a 1.4 1.55 0.75 – 0.92 0.53 0.23 1.4
Beta 
(B.1.351)
>1009 >1007 >1004 5911 0.812 1.28 19 272 4.94 0.74 – 0.92 0.65 63 2.5
Gamma 
(P.1)
>1002 592 >100 >1006 0.66 14 16 – 6.22 0.52 – – 0.3 0.7 2.2
Delta 
(B.1.617.2)
>1002 0.72 – 0.82 0.82 1 – – 0.5 2.9 – – – – 1.4
Kappa 
(B.1.617.1)
>1002 0.62 5 4.62 1.32 12 0.7 – 0.7 5.1 – – – – 2.5
Epsilon 
(B.1.427/9)
>1002 3.32 7.7 1.3 2.1 1 0.82 14 – – – – – – –
N501Y 13 2.97 1 19 0.89 13 1.65
a – 1.13 13 1.43 1.43 13 1.82 –
E484K >1004 2.76 17 1312 112 1.66 0.65 – 6.44 1.54 >1004 0.43 1.43 2.42 –
K417N 0.22 >1005 1 8.97 0.96 0.8 0.64 – 0.33 0.63 0.72 0.32 1.83 0.32 –
L452R >1002 0.94 7.4 1.24 24 1.23 0.6 – – – – – 1.4 – –
T478K – – – – – – – – – – 1.5 – – – –
N439K 1.3 0.43 – 0.84 285 1.7 0.93 – – – 0.92 >100 12 1 –
Y453F 1.8 1.43 – 746 1.66 3.5 1.1 – – – 1.1 – 1 1.5 –
F490S >1002 1.12 1 12 1.42 1 0.82 – – – 42 1.2 – – –
S494P 862 0.62 1 4.53 0.92 1.1 22 – – – 732 0.8 0.7 1.6 –
Table shows fold reductions in neutralization (relative to control virus) for pseudo- typed and infectious viruses with combinations of spike mutations present in  
four World Health Organization (WHO)- defined variants of concern (VOCs; Alpha, Beta, Gamma and Delta), two WHO- defined variants of interest (VOIs;  
Kappa and Epsilon) and viruses containing individual spike mutations. Fold change is the median value of results, subscript is the number of results. ‘–’ indicates 
absence of susceptibility data. aLevels of fold reduction for SOT for N501Y and B.1.1.7 were much higher for IC90 values than for IC50 values. BAM, bamlanivimab 
(LY- CoV555); CAS, casirivimab (REGN10933); CIL, cilgavimab (AZD1061); ETE, etesevimab (LY- CoV016); IMD, imdevimab (REGN10987); REG, regdanvimab (CT- P59); 
SOT, sotrovimab (Vir-7831); TIX, Tixagevimab (AZD8895).
www.nature.com/nrg
R e v i e w s
0123456789();: 
including a deletion within the NTD supersite at 
positions 242–244 (ref.16). The Beta variant was esti-
mated to be 50% more transmissible than the lineages 
that preceded it16.
Reinfections with the Beta variant occurred com-
monly during a phase IIb trial of the NVX- CoV2373 
vaccine performed in South Africa as approximately 
one third of infections in both the vaccine and placebo 
arms were reinfections216. It is not known whether the 
Beta variant is associated with higher virus levels or 
disease severity because once detected it was no longer 
co- circulating with other lineages. As of June 2021, the 
Beta variant accounts for more than 50% of infections in 
many countries in sub- Saharan Africa23,196.
The Beta variant is associated with reduced sus-
ceptibility to many mAbs because E484K interferes 
with binding of several RBM class 1 and 2 mAbs and 
K417N interferes with the binding of several RBM class 1 
mAbs104,117,121,163,217. Of the five FDA EUA- approved mAbs, 
bamlanivimab, etesevimab and casirivimab are largely 
inactive against B.1.351 whereas imdevimab and sotro-
vimab, which bind to the RBD core, retain neutralizing 
activity104,109,117,175,204 (TABLe 1).
The Beta variant has displayed 3-fold to 10-fold 
reduced susceptibility to 46% and >10- fold reduced sus-
ceptibility to 22% of convalescent plasma samples com-
pared with early pandemic variants97,101,104,121,124,203,204,218–220  
(fIg. 5). Of 34 convalescent plasma samples from per-
sons infected with the Alpha variant, 59% had 3- fold 
to 10- fold reduced neutralizing activity and 18% had 
>10- fold reduced neutralizing activity to the Beta 
variant99,104,221. Conversely, plasma from 22 persons 
infected with the Beta variant retained partial or full 
neutralizing activity against variants from earlier waves 
of the pandemic in all but three persons101.
Of plasma samples obtained from persons receiving 
one of the mRNA vaccines, 45% had 3-fold to 10-fold 
and 30% had >10- fold reduced Beta variant neutraliz-
ing activity97,104,117,121,151,204,208,209,222,223 (fIg. 5). Of plasma 
samples from persons receiving the AZD1222 vaccine, 
42% had 3- fold to 10- fold and 54% had >10- fold reduced 
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Fig. 5 | effects of sARs-coV-2 spike variants on 
susceptibility to neutralization. Fold- reduced 
susceptibility of the four variants of concern (VOCs;  
Alpha, Beta, Gamma and Delta) and three common spike 
receptor- binding domain (RBD) mutations (N501Y, E484K 
and L452R) to in vitro neutralization by plasma from 
previously infected persons (part a) and from persons 
vaccinated with the Pfizer/BioNTech BNT162b2 (part b), 
Moderna mRNA-1273 (part c), AstraZeneca AZD1222  
(part d), Janssen Ad26.COV2.S (part e), Novavax NVX- 
CoV2373 (part f), Bharat Biotech BBV152 (part g) and 
Sinovac CoronaVac (part h) vaccines. y axes indicate 
number of plasma units tested. Colour scheme indicates 
fold reduction in neutralization. Only those data from 
plasma samples from persons receiving a full immunization 
schedule were included. Data obtained from https://
covdb.stanford.edu/search- drdb/ on 1 July 2021. In some 
plots, distributions are approximate as they include results 
reported only in aggregate as a mean fold reduction in 
susceptibility.
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The Beta variant has also been associated with 
reduced vaccine efficacy (TABLe 2). In a phase II trial in 
South Africa of AZD1222 in which 39 HIV- negative 
patients became infected with the Beta variant, the 
estimated vaccine efficacy was just 10%224. In a phase II 
trial of NVX- CoV2373 in South Africa in which 38 of 
41 infections were caused by the Beta variant, the esti-
mated vaccine efficacy was 49%216. In a phase III trial 
of the Janssen Ad26.COV2.S vaccine, vaccine efficacy 
in South Africa was 52% and 64% against moderate to 
severe COVID-19 with onset at least 14 and 28 days after 
administration, respectively225. In the previously cited 
Qatar cohort study, the efficacy of BNT162b against 
the Beta variant was estimated to be 72%, which was 
15% lower than that for the Alpha variant211. Among 
nine BNT162b vaccine breakthrough infections in an 
Israeli case–control study, eight were with the Beta vari-
ant even though the Alpha variant predominated during 
the study period226.
Gamma variant (P.1)
The Gamma variant contains the RBD mutations 
N501Y, E484K and K417T (ref.19). It also contains five 
NTD mutations, of which L18F has been shown to inter-
fere with the binding of NTD- targeting neutralizing 
antibodies51. As the Gamma variant was associated with a 
surge of infections in a region of Brazil estimated to have 
achieved a high infection rate, it is suspected of being able 
to infect and cause illness in persons previously infected 
with other variants19,29,30. It was estimated to result in 
virus levels 3–4 times higher than earlier variants and 
to be responsible for an estimated 1.1- fold to 1.8- fold 
higher mortality19. By June 2021, the Gamma variant 
accounted for a high proportion of infections in several 
South American and Caribbean countries196 and 10% 
of US infections33. The resistance profile of the Gamma 
vari ant to the FDA EUA- approved mAbs is similar to that 
of the Beta variant103,109,217,227,228 (TABLe 1). Of convalescent 
plasma samples obtained from persons infected with 
early pandemic variants or with the Alpha variant, about 
20% had 3- fold to 10- fold and 10% had >10- fold reduced 
neutralizing activity97,103,117,203,217,228,229 (fIg. 5). Of plasma 
samples from persons receiving one of the two authorized 
mRNA vaccines, about 60% had 3- fold to 10- fold and 5% 
had >10- fold reduced neutralizing activity97,103,117,167,217,230 
(fIg. 5). A similar distribution in the reduction in neu-
tralizing activity was observed in plasma samples from 
recipients of the AZD1222 vaccine103.
Delta variant (B.1.617.2)
As the pandemic surged in India in early 2021, two var-
iants sharing a common ancestor, Delta (B.1.617.2) and 
Kappa (B.1.617.1), accounted for a high proportion of 
infections. The two variants probably diverged from a 
common ancestor between August and October 2020 
(fIg. 1). Both variants contain the RBD mutation L452R, 
the proximal furin cleavage site mutation P681R and 
several mutations within orf3, orf7a and the nucleocap-
sid gene. The Kappa variant contained the RBD muta-
tion E484Q whereas the Delta variant contained the 
RBD mutation T478K. The two variants also contain 
different mutations within orf1a/b and the spike NTD 
and S2 domains. Even though E484Q is more likely than 
T478K to evade antibody neutralization48,100,165, only the 
Delta variant has demonstrated increased transmissi-
bility, spreading to 54 countries and rapidly replacing 
the Alpha variant in the UK32,35 and the USA33.
Among the FDA EUA- approved mAbs, the Delta var-
iant is associated with high- level reduced bamlanivimab 
susceptibility100,214. It results in approximately 3- fold to 
10- fold reduced susceptibility to 45% and >10- fold 
reduced susceptibility to 5% of convalescent plasma 
samples100,118,214,215,231 (fIg. 5). Among plasma samples 
obtained from recipients of the BNT162b vaccine, approx-
imately 15% displayed 3- fold to 10- fold reduced neu-
tralizing activity against the Delta variant100,118,214 (fIg. 5). 
Test- negative case–control 
study
(TNCC). A study design in 
which cases are patients 
presenting with a clinical 
syndrome who test positive for 
sArs- CoV-2 whereas controls 
are patients presenting with 
the same syndrome who test 
negative for sArs- CoV-2.  
The proportions of cases and 
controls who have been 
vaccinated are compared.











Pre-variant 95% (trial)56,59 70% (trial)59,248 96% (trial)59,212 72% (trial)59,225 51% (trial)59
Alpha 90% (TNCC)211 70% (trial)213 86% (trial)212 – –
92% (TNCC)233 66% (TNCC)232
93% (TNCC)232 81% (TNCC)233
97% (cohort)210
Beta 75% (TNCC)211 10% (trial)224 51% (trial)216 64% (trial)225 –
Gamma – – – – 42% (TNCC)249
Delta 83% (TNCC)233 60% (TNCC)232 – – –
88% (TNCC)232 61% (TNCC)233
Table shows vaccine efficacy at preventing symptomatic SARS- CoV-2 infection with the Alpha, Beta, Gamma and Delta variants  
of concern (VOCs). Comparison is with efficacy against ‘pre- variant’ isolates. Data include persons receiving a full course of 
vaccination: 1–2 weeks following two vaccine doses for BNT162b, AZD1222, NVX-2373 and CoronaVac; 4 weeks after one vaccine 
dose for AD26.CoV2. ‘Trial’ refers to post- hoc analysis of clinical trial data. TNCC, test- negative case–control study; ‘–’, Not 
available. aAZD1222 efficacy data include some patients receiving the standard vaccine dose at both time points and others 
receiving a lower vaccine dose at the first time point. bAD26.CoV2 efficacy data based on preventing moderate to severe disease; 
pre- variant efficacy based on US data. cCoronaVac efficacy data against pre- variant isolates may include some persons infected 
with the Gamma VOC and the Zeta variant of interest (VOI). The TNCC study of vaccine efficacy against the Gamma VOC was 
performed in persons aged 70 years or older.
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By contrast, among plasma samples obtained from 
recipients of the AZD1222 vaccine, higher proportions 
displayed reduced neutralizing activity against this 
variant100,209,214. In case–control studies from the UK, 
the BNT162b vaccine was approximately 85% effective 
for the Delta variant whereas the AZD1222 vaccine was 
approximately 60% effective232,233.
AY.1 and AY.2 are recently reported sub- lineages 
of the Delta variant that have developed additional 
mutations including the RBD mutation K417N (ref.196).
Variants of interest
The Epsilon variant comprises two closely related lin-
eages B.1.427 and B.1.429, first detected in California, 
USA. This variant was the first reported to contain the 
RBD mutation L452R. It was estimated to be about 
20% more transmissible than co- circulating lineages 
and to be associated with twofold higher upper- airway 
virus levels123,192. By February 2021, the Epsilon variant 
accounted for 15% of US infections, but by June 2021 its 
prevalence decreased to below 1%.
In contrast to the Delta VOC, the Kappa VOI has 
not demonstrated increased transmissibility. However, 
because of the presence of the RBD mutations L452R 
and E484Q, the Kappa variant has a somewhat greater 
ability to evade humoral immunity than the Delta var-
iant. It displays reduced susceptibility to casirivimab 
and to bamlanivimab. Of convalescent plasma samples, 
about 40% had 3- fold to 10- fold and 15% had >10- fold 
reduced neutralizing activity100,122,234. Of plasma samples 
from recipients of an mRNA vaccine, approximately 
55% had 3- fold to 10- fold and 5% had >10- fold reduced 
neutralizing activity100,118,122,234.
The Iota (B.1.526), Eta (B.1.525) and Zeta (P.2) vari-
ants are each characterized primarily by the RBD muta-
tion E484K. The Iota variant was first identified in New 
York state. In June 2021, it had a prevalence of 5–10% 
in the USA but remained rare outside the USA154. It 
contains the same nsp6 deletion as in the Alpha, Beta 
and Gamma variants. Of convalescent plasma samples, 
about 40% display 3- fold to 10- fold and 10% display 
>10- fold reduced Iota variant neutralizing activity166,235. 
Of plasma samples from recipients of an mRNA vaccine, 
about 30% display 3- fold to 10- fold reduced neutralizing 
activity230,235. The Eta variant is present at low levels in 
many countries, with Nigeria having the highest pro-
portion of infections236. The ability of mAb, convalescent 
plasma and vaccinee plasma to neutralize the Eta variant 
has been infrequently studied118,166. The Zeta variant was 
common in Brazil in late 2020 and early 2021 (ref.157), but 
appears to be decreasing in prevalence.
The Theta variant was first reported in March 2021 
in the Philippines. It contains 13 lineage- defining muta-
tions including N501Y, E484K, P681H and the NTD 
deletion at positions 141–143 (refs155,156). However, 
it remains rare, accounting for a small proportion of 
infections even in the Philippines196. The Lambda vari-
ant (C.37) has a unique set of spike mutations including 
L452Q and F490S within the RBD and the NTD deletion 
Δ246–252 (ref.237). It is highly prevalent in several South 
American countries and is associated with reduced 
susceptibility to the locally used CoronaVac vaccine238.
Conclusions and implications for COVID-19
SARS- CoV-2 variants are characterized by their trans-
missibility, disease severity and ability to evade humoral 
immunity. The Alpha and Delta variants are each 
associated with increased transmissibility and greater 
disease severity because of immune evasion, and poten-
tially because of higher virus levels resulting from the 
antagonism of innate immunity. The Beta and Gamma 
variants are each associated with increased transmissi-
bility because of their ability to evade humoral immu-
nity and cause reinfections. Although it is not surprising 
that mutations associated with reduced humoral immu-
nity have recently emerged in association with rising 
population immunity, the concurrent emergence of 
mutations that intrinsically increase SARS- CoV-2 
replication is more difficult to explain. The timing of 
this second category of mutations raises the possibility 
that they only emerged after a critical number of global 
infections or as compensation for subtle reductions in 
replication fitness associated with developing immune 
escape mutations.
As of June 2021, it is uncertain whether the current 
approaches to classifying variants will be sustainable. 
Should the current VOCs and VOIs develop multi-
ple sub- lineages with additional biologically relevant 
mutations, it may become necessary to classify variants 
according to their component mutations rather than 
their ancestral lineages. However, despite the phenome-
nal progress in studying the impact of individual muta-
tions in vitro and in animal models, classifying variants 
according to their component mutations will also prove 
challenging should the number of recurrent mutations 
also increase.
Although SARS- CoV-2 variants differ in their trans-
mission rates, disease severity and risk of reinfection, 
there is no evidence that they are differentially affected 
by non- pharmaceutical public health measures such 
as social distancing and the use of personal protective 
equipment, or that they will respond differently to most 
antiviral therapies. Except for several mAb preparations 
(for example, bamlanivimab/etesevimab), most antivi-
ral compounds are likely to retain activity against each 
of the current VOCs and VOIs. The two most recently 
approved mAb preparations, casirivimab/imdevimab 
and sotrovimab, retain activity against all VOCs and 
VOIs, in part because imdevimab and sotrovimab tar-
get the RBD core whereas the most prevalent immune 
escape mutations are in the RBD RBM. There have also 
been no reports of variants with mutations in the enzy-
matic targets of therapy that would reduce susceptibility 
to remdesivir or to the RNA- dependent RNA polymerase 
and protease inhibitors in clinical development.
The most important consequence of emergent 
SARS- CoV-2 variants, therefore, is their impact on 
vaccine efficacy. The levels of neutralizing mAbs elic-
ited by the mRNA vaccines has been high and in most 
persons are likely to be maintained for many months 
above the levels required for protection against even the 
most resistant circulating variants164,239,240. In addition, 
the mRNA vaccines appear to often elicit memory B cells 
that undergo somatic hypermutation, which should 
broaden the response to viruses with variant spike 
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proteins239,240. Nonetheless, in vitro neutralization stud-
ies and epidemiological vaccine efficacy studies indicate 
weaker protection against emerging variants for most 
of the non- mRNA vaccines. Moreover, regardless of the 
vaccine received, reductions in vaccine- elicited humoral 
immunity is likely to be clinically significant for per-
sons with impaired immunity as a result of underlying 
disease, immunosuppressive drugs or older age241–244.
As the spectrum of SARS- CoV-2 variants is expand-
ing and shifting faster than epidemiological studies 
can be conducted, laboratory correlates of protection 
against SARS- CoV-2 variants have become a high 
priority. As summarized in this Review, neutraliz-
ing antibody titres against pre- variant and variant 
SARS- CoV-2 isolates correlate with protection from 
infection in epidemiological studies. Whether this is 
because neutralizing antibodies are the most important 
means of viral protection and/or because these titres 
correlate with other aspects of protective immunity, 
including memory B cells, antibody- mediated effector 
functions and T cell immunity is not known. Therefore, 
a strategy that combines genomic surveillance, in vitro 
neutralization studies and vaccine efficacy studies 
should be maintained to identify those variants that 
pose the greatest threat to current vaccines and to guide 
the development of immunogens for second- generation 
vaccines245.
An mRNA vaccine that incorporated most of the 
spike mutations present in the Beta variant (mRNA-
1273.351; Moderna) was recently reported to increase 
both pre- variant and Beta variant- specific neutralizing 
antibody titres when administered as a booster to mice 
that had previously been immunized with mRNA-1273 
(ref.246). Continued studies in animal species that are 
more predictive of responses in humans will be necessary 
to determine whether updated immunogens can broaden 
the response to multiple variants rather than just boost 
existing antibody responses generated by previous infec-
tions or vaccinations247. Moreover, as the spike protein 
has been found to contain multiple cytotoxic and helper 
T cell epitopes, it will be important that as many of these 
as possible are included in future vaccine preparations89.
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